You are here

Home » Van Andel Research Institute

Van Andel Research Institute

333 Bostwick Ave
Grand Rapids, MI 49503
United States

Development of Mithramycin Analogs for Ewing sarcoma

Ewing Sarcoma

Background


A promising drug target for Ewing’s sarcoma is a protein called EWS-FLI1. This is a type of protein called a transcription factor which is thought by many to be an “undruggable target.”

Optimizing the Trabectedin Induced Differentiation of Ewing sarcoma Cells into Adipocytes

Ewing Sarcoma

Background

Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma

Ewing Sarcoma

Background


Ewing sarcoma is the second most common childhood bone tumor with a poor prognosis particularly for patients who have relapsed or metastatic disease. The goal of our lab is to develop and clinically translate novel therapies for Ewing sarcoma.

Featured Hero

Chris Ramirez

Chris loves baseball – he has a history of playing for his high school team and is a longtime fan of the San Francisco Giants. However, when he was in high school, Chris began having strange symptoms. Today, Chris is a three-time survivor of glioblastoma.
Read more »